| A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer (NCT00632541) | Hoosier Cancer Research Network | 2007-10-01 |
| Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer (NCT00534417) | Accelerated Community Oncology Research Network | 2007-10-01 |
| Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer (NCT00764972) | McGill University | 2007-10-01 |
| Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC (NCT00601159) | Fudan University | 2007-09-01 |
| Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer (NCT00517361) | University of Chicago | 2007-08-01 |
| Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer (NCT00496366) | Rutgers, The State University of New Jersey | 2007-07-23 |
| Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer (NCT00426556) | Novartis Pharmaceuticals | 2007-07-01 |
| A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (NCT00509769) | Genentech, Inc. | 2007-07-01 |
| ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer (NCT00496665) | Dana-Farber Cancer Institute | 2007-07-01 |
| A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. (NCT00428220) | Pfizer | 2007-07-01 |
| Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients (NCT01611727) | Pomeranian Medical University Szczecin | 2007-07-01 |
| Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer (NCT00477464) | GlaxoSmithKline | 2007-06-01 |
| Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer (NCT00597597) | Rush University Medical Center | 2007-04-01 |
| Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer (NCT00467012) | Chugai Pharmaceutical | 2007-04-01 |
| Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment (NCT00452140) | Neovii Biotech | 2007-03-01 |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) (NCT00434356) | Genentech, Inc. | 2007-03-01 |
| A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer (NCT00370552) | R-Pharm | 2007-03-01 |
| A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer (NCT00454532) | Bionovo | 2007-03-01 |
| Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer (NCT00442260) | West Virginia University | 2007-02-01 |
| Southeast Netherlands Advanced Metastatic Breast Cancer Registry (NCT03577197) | Academisch Ziekenhuis Maastricht | 2007-01-01 |
| VEGF Trap in Treating Patients With Metastatic Breast Cancer (NCT00369655) | National Cancer Institute (NCI) | 2007-01-01 |
| Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (NCT00691912) | Claudia Lorenz-Schlüter | 2006-12-01 |
| A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline (NCT01027208) | R-Pharm | 2006-12-01 |
| Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis (NCT00524849) | Fudan University | 2006-11-01 |
| A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer (NCT00618826) | Barbara Ann Karmanos Cancer Institute | 2006-11-01 |
| Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer (NCT00404066) | George Albert Fisher | 2006-10-01 |
| Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer (NCT00387907) | Sanofi | 2006-10-01 |
| E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (NCT00337103) | Eisai Inc. | 2006-09-20 |
| Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy (NCT00570258) | University of Arkansas | 2006-09-01 |
| Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (NCT00574236) | University of Wisconsin, Madison | 2006-08-01 |
| Phase I Combination w/ Epirubicin (NCT00322374) | R-Pharm | 2006-08-01 |
| Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer (NCT00358098) | AHS Cancer Control Alberta | 2006-08-01 |
| Phase I Study of Aprotinin in Advanced Breast Cancer (NCT00354900) | Dartmouth-Hitchcock Medical Center | 2006-07-01 |
| Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer (NCT00367250) | Medical University of Vienna | 2006-07-01 |
| IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma (NCT00349934) | Immutep S.A.S. | 2006-07-01 |
| Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer (NCT00334802) | Eli Lilly and Company | 2006-06-01 |
| Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer (NCT00364195) | YM BioSciences | 2006-06-01 |
| ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer (NCT00394082) | Celgene | 2006-06-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (NCT00313170) | AstraZeneca | 2006-05-30 |
| A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen (NCT00932373) | Genentech, Inc. | 2006-04-01 |
| Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer (NCT00316199) | Eli Lilly and Company | 2006-04-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg (NCT00305448) | AstraZeneca | 2006-03-01 |
| Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) (NCT00307229) | Ontario Clinical Oncology Group (OCOG) | 2006-03-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer (NCT00274469) | AstraZeneca | 2006-02-06 |
| Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer (NCT00403130) | George Albert Fisher | 2006-02-01 |
| A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) (NCT00281697) | Genentech, Inc. | 2006-02-01 |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy (NCT00225758) | Gary Schwartz | 2006-01-01 |
| SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer (NCT00270413) | Universitaire Ziekenhuizen KU Leuven | 2006-01-01 |
| A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) (NCT00262067) | Genentech, Inc. | 2005-12-01 |
| Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer (NCT00303108) | US Oncology Research | 2005-12-01 |
| CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer (NCT00270907) | M.D. Anderson Cancer Center | 2005-12-01 |
| Satraplatin for Patients With Metastatic Breast Cancer (MBC) (NCT00265655) | Agennix | 2005-11-01 |
| Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer (NCT00274456) | Celgene | 2005-11-01 |
| Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. (NCT00240071) | University of Alabama at Birmingham | 2005-10-01 |
| Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant (NCT01019577) | R-Pharm | 2005-10-01 |
| Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC (NCT00532272) | National Cancer Center, Korea | 2005-10-01 |
| Standard Versus Continuous Capecitabine in Advanced Breast Cancer (NCT00418028) | Hospital San Carlos, Madrid | 2005-09-01 |
| Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer (NCT01451580) | TTY Biopharm | 2005-09-01 |
| PhII ICb With/Without Erbitux in MBC Pts (NCT00248287) | US Oncology Research | 2005-07-28 |
| A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer (NCT00661739) | GBG Forschungs GmbH | 2005-07-01 |
| Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (NCT01439191) | Shanghai CP Guojian Pharmaceutical Co., Ltd. | 2005-07-01 |
| A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study (NCT02392845) | Hospices Civils de Lyon | 2005-06-01 |
| Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer (NCT00303615) | Legacy Health System | 2005-06-01 |
| Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer (NCT00212095) | National University Hospital, Singapore | 2005-06-01 |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen (NCT00191269) | Eli Lilly and Company | 2005-06-01 |
| Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer (NCT00156273) | University of Michigan Rogel Cancer Center | 2005-04-01 |
| XELOX for Metastatic Breast Cancer (NCT00204776) | University of Wisconsin, Madison | 2005-03-01 |
| A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer (NCT00251472) | Veeda Oncology | 2005-03-01 |
| Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe) (NCT00162929) | Ontario Clinical Oncology Group (OCOG) | 2005-01-01 |
| Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer (NCT01025349) | Taipei Medical University Hospital | 2005-01-01 |
| An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine (NCT00165880) | Eisai Limited | 2004-12-01 |
| Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer (NCT00148707) | Dana-Farber Cancer Institute | 2004-10-01 |
| Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes (NCT00192101) | Eli Lilly and Company | 2004-10-01 |
| Dendritic Cell Based Therapy of Metastatic Breast Cancer (NCT00197925) | Herlev Hospital | 2004-09-01 |
| Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer (NCT00532623) | National Cancer Center, Korea | 2004-05-01 |
| To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older (NCT00082095) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-04-01 |
| Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer (NCT00212069) | National University Hospital, Singapore | 2004-03-01 |
| Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer (NCT00216021) | Hoosier Cancer Research Network | 2004-03-01 |
| Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer (NCT00216073) | Hoosier Cancer Research Network | 2004-03-01 |
| Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer (NCT00524810) | ARCAGY/ GINECO GROUP | 2004-02-01 |
| Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer (NCT00250874) | Zeneus Pharma | 2003-12-01 |
| A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer (NCT00159094) | Hematology Oncology Consultants | 2003-10-01 |
| Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma (NCT00225056) | Oncology Specialties, Alabama | 2003-10-01 |
| The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer (NCT00065325) | AstraZeneca | 2003-08-01 |
| Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer (NCT00525096) | ARCAGY/ GINECO GROUP | 2003-07-01 |
| Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer (NCT00319618) | AstraZeneca | 2003-06-01 |
| Phase II Study for Solid Metastatic Tumors (NCT02474186) | NYU Langone Health | 2003-04-01 |
| Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer (NCT00171847) | Novartis Pharmaceuticals | 2003-03-01 |
| Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers (NCT00169000) | Dartmouth-Hitchcock Medical Center | 2003-01-01 |
| A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer (NCT00214864) | Cancer Research Network | 2002-12-01 |
| Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer (NCT01433614) | Thomas Hatschek | 2002-12-01 |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer (NCT00401427) | National Cancer Institute, Naples | 2002-11-01 |
| Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. (NCT00051103) | GlaxoSmithKline | 2002-10-01 |
| Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer (NCT00480597) | Ludwig-Maximilians - University of Munich | 2002-10-01 |
| Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function (NCT00169104) | Dartmouth-Hitchcock Medical Center | 2002-07-01 |
| Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy (NCT00333047) | Novartis | 2002-07-01 |
| Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer (NCT00212082) | National University Hospital, Singapore | 2002-04-01 |
| Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment (NCT00241046) | Novartis Pharmaceuticals | 2002-04-01 |
| Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) (NCT01127074) | University Hospital Tuebingen | 2002-03-01 |
| Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer (NCT01237327) | Pfizer | 2001-11-01 |